Health Technology Assessment Archives -

Prof Gillian Leng’s replacement as chief executive of the National Institute for Health and Care Excellence (NICE) has

Samantha Roberts to replace Gillian Leng as CEO of NICE

https://pharmaphorum.com/news/samantha-roberts-to-replace-gillian-leng-as-ceo-of-nice/

Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUS

Phil Taylor Alexion, AstraZeneca, Health Technology Assessment, HEOR, nephrology, NHS, rare disease, Scotland, Soliris, Ultomiris 0 Comment

NHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to

Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUS

https://pharmaphorum.com/news/scotland-backs-nhs-use-of-alexions-ultomiris-for-rare-disease-ahus/

Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

NICE talking to you: Trends in early HTA engagement

Leela Barham Health Technology Assessment, NICE 0 Comment

With exclusive data from Freedom of Information (FOI) requests sent to the National Institute for Health and are

NICE talking to you: Trends in early HTA engagement

https://pharmaphorum.com/views-analysis-market-access/nice-talking-to-you/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Improving access and reimbursement for specialty therapies

mike.hammerton@pharmaphorum.com Deep Dive: Market Access, Health Technology Assessment, ICON, payers 0 Comment

As specialty therapies move toward long-term maintenance use and as treatment times grow longer, government and commercial payers

Improving access and reimbursement for specialty therapies

https://pharmaphorum.com/views-analysis-market-access/improving-access-and-reimbursement-for-specialty-therapies/

Market Access/ News/ News

NICE names Gillian Leng as CEO, replacing Andrew Dillon

Phil Taylor Gillian Leng, Health Technology Assessment, NICE, senior management 0 Comment

NICE has appointed Prof Gillian Leng as its new chief executive, completing its top leadership search after new

NICE names Gillian Leng as CEO, replacing Andrew Dillon

https://pharmaphorum.com/news/nice-names-gillian-leng-as-ceo-replacing-andrew-dillon/

Market Access/ News/ News

MPs back Nebhrajani as NICE’s new chair after vetting meeting

Phil Taylor appointment, Health Technology Assessment, NICE, senior management 0 Comment

Sharmila Nebhrajani has been confirmed as the new chair of the National Institute for Health and Care Excellence

MPs back Nebhrajani as NICE’s new chair after vetting meeting

https://pharmaphorum.com/news/mps-back-nebhrajani-as-nices-new-chair-after-vetting-meeting/

Market Access/ News/ News

NICE chair nominee Nebhrajani to face MP scrutiny next week

Phil Taylor Health Technology Assessment, NICE, senior management 0 Comment

The UK government’s preferred candidate to chair NICE – Sharmila Nebhrajani OBE – is due to be quizzed

NICE chair nominee Nebhrajani to face MP scrutiny next week

https://pharmaphorum.com/news/nice-chair-nominee-nebhrajani-to-face-mp-scrutiny-next-week/

Market Access/ News/ News/ News/ News/ Patients/ Sales and Marketing/ Top stories

ICER methods could be illegal in US, claims US think tank

Phil Taylor Health Technology Assessment, ICER, pricing, QALY, US, Value-based pricing 0 Comment

The method used by the US Institute for Clinical and Economic Review (ICER) to gauge whether drugs are

ICER methods could be illegal in US, claims US think tank

https://pharmaphorum.com/news/icer-methods-could-be-illegal-in-us-claims-us-think-tank/

Market Access/ News/ News/ News/ Oncology

Scotland backs AZ’s Lynparza for first-line ovarian cancer maintenance

Phil Taylor AstraZeneca, Health Technology Assessment, Lynparza, Merck & Co, Oncology, ovarian cancer, Scotland, Scottish Medicines Consortium 0 Comment

The Scottish Medicines Consortium (SMC) has backed routine funding of AstraZeneca and MSD’s Lynparza as a maintenance treatment

Scotland backs AZ’s Lynparza for first-line ovarian cancer maintenance

https://pharmaphorum.com/news/scotland-backs-azs-lynparza-for-first-line-ovarian-cancer-maintenance/

Trending

Health Technology Assessment

Login